These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16618770)

  • 1. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
    Kawakami K; Terabe M; Kawakami M; Berzofsky JA; Puri RK
    Cancer Res; 2006 Apr; 66(8):4434-42. PubMed ID: 16618770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
    Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
    Wu TY; Fleischmann WR
    J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
    Nakashima H; Fujisawa T; Husain SR; Puri RK
    J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
    Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
    Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
    Kawakami K; Kawakami M; Husain SR; Puri RK
    Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
    Yin X; Yan X; Yang Q; Cao H; Liang H
    Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
    Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
    J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
    Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
    Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo.
    Ma HL; Whitters MJ; Jacobson BA; Donaldson DD; Collins M; Dunussi-Joannopoulos K
    Int Immunol; 2004 Jul; 16(7):1009-17. PubMed ID: 15184346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2.
    Chang MR; Lee WH; Choi JW; Park SO; Paik SG; Kim YS
    Exp Mol Med; 2005 Jun; 37(3):240-9. PubMed ID: 16000879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.